Pfizer/$PFE
1D1W1MYTD1Y5YMAX
Capital at risk
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
- Ticker
- $PFE
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 75,000
- Headquarters
- New York, United States
- Website
- www.pfizer.com
Pfizer Metrics
BasicAdvanced
$162B
37.44
$0.76
0.28
$1.72
6.05%
Price and volume
Market cap
$162B
Beta
0.28
52-week high
$29.21
52-week low
$23.58
Average daily volume
38M
Dividend rate
$1.72
Financial strength
Current ratio
1.267
Quick ratio
0.854
Long term debt to equity
71.085
Total debt to equity
74.253
Dividend payout ratio (TTM)
225.77%
Interest coverage (TTM)
6.98%
Profitability
EBITDA (TTM)
25,383
Gross margin (TTM)
74.72%
Net profit margin (TTM)
6.80%
Operating margin (TTM)
29.58%
Effective tax rate (TTM)
-3.89%
Revenue per employee (TTM)
$850,000
Management effectiveness
Return on assets (TTM)
5.78%
Return on equity (TTM)
5.01%
Valuation
Price to earnings (TTM)
37.441
Price to revenue (TTM)
2.542
Price to book
1.9
Price to tangible book (TTM)
-4.87
Price to free cash flow (TTM)
14.738
Free cash flow yield (TTM)
6.79%
Free cash flow per share (TTM)
1.93
Dividend yield (TTM)
6.05%
Forward dividend yield
6.05%
Growth
Revenue change (TTM)
-0.21%
Earnings per share change (TTM)
-59.88%
3-year revenue growth (CAGR)
-6.70%
10-year revenue growth (CAGR)
1.99%
3-year earnings per share growth (CAGR)
-41.30%
10-year earnings per share growth (CAGR)
-3.88%
3-year dividend per share growth (CAGR)
2.02%
10-year dividend per share growth (CAGR)
4.02%
What the Analysts think about Pfizer
Analyst ratings (Buy, Hold, Sell) for Pfizer stock.
Analyst projections of the future price of Pfizer stock.
Bulls say / Bears say
The FDA approved Pfizer and Arvinas’ breast cancer drug for patients with ESR1-mutated, ER+/HER2- advanced breast cancer, expanding Pfizer’s high-margin oncology portfolio (Reuters)
On June 24, 2026, the FDA granted a new indication for Ibrance® (palbociclib) plus trastuzumab and endocrine therapy as first-line maintenance in HR+/HER2+ metastatic breast cancer, making it the first CDK4/6 inhibitor approved regardless of HER2 status (Reuters)
Pfizer is exploring manufacturing, technology transfer and healthcare partnerships across the Middle East and Africa to localize production and capture demographic-driven emerging markets growth (Reuters)
Pfizer’s experimental antibody–drug conjugate sigvotatug vedotin missed the primary endpoint in its Phase III lung cancer trial, highlighting execution risk in its oncology pipeline (Reuters)
In Q2 2026, Pfizer took a $3.8 billion write-down on its experimental lung cancer therapy sigvotatug vedotin after unfavorable Phase III results, underscoring high attrition and R&D pipeline volatility (Reuters)
If Pfizer’s Prevnar formulation patent is invalidated on appeal, settled generic companies could launch copycat pneumococcal vaccines as early as November 21, 2026, threatening its multibillion-dollar vaccine franchise (SEC Filing)
Data summarised monthly by Lightyear AI. Last updated on 21 Aug 2026.
Pfizer Financial Performance
Revenues and expenses
Pfizer Earnings Performance
Company profitability
Upcoming events
No upcoming events
Pfizer News
AllArticlesVideos
Funds containing Pfizer
AllEURGBPUSD
Fund name | Fund size | $PFE weighting |
|---|---|---|
VanEck Morningstar Developed Markets Dividend Leaders€TDIV | €754M | 4.12% |
VanEck Morningstar Developed Markets Dividend Leaders£TDGB | £655M | 4.12% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 2.38% |
iShares Dow Jones U.S. Select Dividend€EXX5 | €414M | 2.29% |
iShares MSCI USA Quality Dividend ESG£HDIQ | £579M | 2.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.